GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CERo Therapeutics Holdings CERO · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

-18.66%

Close of 5 Nov 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$19.9m

FY2021FY2025

Free cash flow

−$16.1m

FY2021FY2025

Shareholders' equity

−$5.4m

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Gross profit−$1.1m−$1.2m−$1.1m——
Research and development$10.4m$6.3m$5.3m$9.8m$9.1m
Operating income−$18.5m−$15.3m−$2.9m−$2.9m−$332,030
Net income−$19.9m−$7.7m−$2,536−$667,736−$315,547
Diluted earnings per share-0.94-56.07-0.34-90.23-42.64

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assets$3.6m$6.2m$5.1m$42.4m$180.1m
Cash and short-term investments$1.7m$3.3m$1.6m$42.1m$1.1m
Total liabilities$9.1m$8.1m$47.2m$39.9m$9.2m
Debt$699,107$1.6m$1.6m$650,000$3.6m
Shareholders' equity−$5.4m−$1.9m−$5.8m$2.5m$170.8m
Shares outstanding21m0m0m0m0m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operations−$16.1m−$5.8m−$5.8m−$1.1m−$697,109
Capital spending—−$1−$3−$694,232−$612,566
Free cash flow−$16.1m−$5.8m−$5.8m−$1.8m−$1.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue—————$1.2m——
Gross profit−$278,691−$276,142—−$272,766−$267,657−$269,475—−$297,340
Operating income−$3.8m−$4.8m−$4.4m−$4.4m−$4.7m−$5.0m−$2.1m−$4.4m
Net income−$1.0m−$5.9m−$4.5m−$4.9m−$5.4m−$5.1m−$2.1m−$4.2m
Diluted earnings per share-0.02-0.14-0.22-0.23-0.26-0.24-72.93-30.66
Cash from operations−$2.0m−$2.0m−$3.0m−$3.0m−$4.0m−$4.0m—−$2.0m
Total assets$1.9m$2.2m$3.6m$3.9m$6.2m$8.0m$6.2m$6.5m
Cash and short-term investments$937,512$857,489—$2.0m$3.8m$5.2m—$3.4m
Debt$8.6m$598,345—$931,023$934,310$905,005—$1.0m
Shareholders' equity−$30.5m−$9.3m−$5.4m−$4.5m−$1.6m−$329,386−$1.9m−$3.7m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income85.2%——
Net income210.1%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-0.1-1.2-7297.7-25.9-52.8

Share price return

Finished calendar years

20252024202320222021
Return-100%-97%7%4%-0%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 20-to-1 reverse split · 13 Jun 2025
  • 100-to-1 reverse split · 8 Jan 2025
  • 1-to-1 reverse split · 15 Feb 2024

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.